secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACELYRIN, Inc. (—)
CIK:        0001962918
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001962918-24-000104
Event type: other_material
Sentiment:  neutral
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ACELYRIN reports positive Phase 3 izokibep data; pivots to lonigutamab, cuts 1/3 workforce
--------------------------------------------------------------------------------

- Phase 3 trial of izokibep in hidradenitis suppurativa met primary endpoint HiSCR75 (33% vs 21% placebo, p=0.0294); HiSCR90 (25% vs 9%, p=0.0009).
- Company suspends new izokibep investment; focuses on lonigutamab for thyroid eye disease, plans Phase 3 initiation Q1 2025.
- Workforce reduced by ~40 employees (~1/3); expects ~$4.5M severance charges mostly in Q3 2024.
- COO Melanie Gloria steps down effective Oct 31, 2024; receives severance including 12 months salary and equity extension.
- Q2 2024 net loss $85.7M; R&D $76.4M; cash $635.2M projected to fund operations through mid-2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962918/000196291824000104/0001962918-24-000104-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962918/000196291824000104/slrn-20240809.htm
  HTML page:      https://secwatch.observer/filing/0001962918-24-000104

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer